Skip to main content
Premium Trial:

Request an Annual Quote

Benitec, Biomics Advance HBV Partnership

Premium

Benitec and its Chinese partner Biomics Biotechnologies have agreed to advance their collaboration to develop an expressed RNAi treatment for hepatitis B.

The companies began working together on the program in mid-2009, and finalized the arrangement a few months later (GSN 7/16/2009 & 9/9/2010). The first stage of the alliance identified target RNA sequences capable of blocking HBV replication, Benitec said.

Now, the partners aim to conduct proof-of-principle studies to optimize a preclinical drug candidate, a process expected to take around 18 months.

According to Benitec, the firms have agreed to share development costs, ownership of related intellectual property, and commercialization rights based on “an agreed division of territories.” Additional terms of the deal were not disclosed.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.